At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 224 enrolled
Drug / intervention
NCX 4251 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension, 0.1% QD for the Treatment of Acute Exacerbations of Blepharitis (Mississippi)
In Brief
A Phase 2 clinical trial evaluating NCX 4251 and Placebo for Blepharitis. Completed, enrolled 224 participants across 1 site.
Detailed Summary
This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2b trial evaluating the safety and efficacy of NCX 4251 (fluticasone propionate nanocrystal) Ophthalmic Suspension 0.1% QD for the treatment of acute exacerbations of blepharitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlepharitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartDec 2020
First PostedDec 2020
Primary CompletionJun 2021
Study CompletionJun 2021
TodayJul 2026
First PostedDec 19, 2020
Enrollment StartDec 14, 2020
Primary CompletionJun 16, 2021
Study CompletionJun 30, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.5 years ago
Interventions
NCX 4251drug
NCX 4251 Ophthalmic Suspension, 0.1% dosed once daily
Placebodrug
Vehicle of NCX 4251 Ophthalmic Suspension dosed once daily